300009 安科生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)11.11524.39523.4617.35013.143
总资产报酬率 ROA (%)8.49618.40317.7465.76110.666
投入资产回报率 ROIC (%)10.81123.68522.8647.23312.950

边际利润分析
销售毛利率 (%)78.24678.35378.40680.06278.778
营业利润率 (%)37.95732.24236.12113.71524.923
息税前利润/营业总收入 (%)37.79531.96835.66813.28123.767
净利润/营业总收入 (%)32.62729.96031.6459.37820.367

收益指标分析
经营活动净收益/利润总额(%)92.802101.66692.447207.49499.197
价值变动净收益/利润总额(%)1.721-0.5604.9298.622-0.180
营业外收支净额/利润总额(%)-0.199-0.440-0.977-0.786-1.899

偿债能力分析
流动比率 (X)2.9222.7452.8273.0663.473
速动比率 (X)2.5072.4682.5162.7773.145
资产负债率 (%)18.46120.57120.08920.8640.164
带息债务/全部投入资本 (%)-1.291-1.701-2.329-2.970-2.341
股东权益/带息债务 (%)-7,537.287-5,718.036-4,160.325-3,302.521-4,218.060
股东权益/负债合计 (%)419.319366.977375.201364.013492.068
利息保障倍数 (X)-435.906-240.501-347.433-40.631-34.396

营运能力分析
应收账款周转天数 (天)76.25359.99464.78269.67886.620
存货周转天数 (天)172.741129.323140.078140.021139.336